Quick Answer
Nurix Therapeutics, Inc. reported Shares Outstanding of 101.81 million shares for fiscal year 2025.
Nurix Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 101.81M | +34.2% |
| 2024 | 75.87M | +55.7% |
| 2023 | 48.72M | +3.3% |
| 2022 | 47.17M | +5.6% |
| 2021 | 44.66M | +14.9% |
| 2020 | 38.86M | +981.0% |
| 2019 | 3.60M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| August 31, 2025 | 76.87M | +14.6% | +0.6% |
| May 31, 2025 | 76.43M | +18.8% | +0.3% |
| February 28, 2025 | 76.23M | +55.1% | +0.5% |
| November 30, 2024 | 75.87M | +55.7% | +13.1% |
| August 31, 2024 | 67.08M | +38.3% | +4.2% |
| May 31, 2024 | 64.36M | +35.1% | +31.0% |
| February 29, 2024 | 49.14M | +3.6% | +0.9% |
| November 30, 2023 | 48.72M | +3.3% | +0.4% |
- Nurix Therapeutics, Inc. showed an increase of +34.2% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, Nurix Therapeutics, Inc.’s shares outstanding has grown by 2731.7% (from 3.60 million shares to 101.81 million shares).
- The most recent figure is from Nurix Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 28, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: